title: [Proposal for the treatment of cervix dysplasia with immunomodulators].
abstract: The study included 60 patients: 43 suffered from slight portio dysplasia (12 had HPV infection also), while 17 had moderate dysplasia (7 had HPV infections also). The treatment was carried out by self-administration in 3 stages: attack (50 mg of thymopentin by s.c. injection every day for two weeks); maintenance (50 mg of thymopentin by s.c. injection every other day for ten weeks); recall 6 months after (50 mg of thymopentin every day for 4 weeks). The drug was well tolerated by all of the patients and the recovery rate in a 9-months follow-up period was significantly higher versus an historical control group.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Genova.
authors.forename: G E
authors.initials: GE
authors.lastname: Serra
authors.forename: C
authors.initials: C
authors.lastname: Gustavino
authors.forename: G G
authors.initials: GG
authors.lastname: Serra Cervetti
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016305:Thymopentin / Q000627:therapeutic use*; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D016305:Thymopentin
vernacular_title: Proposta di terapia con immunomodulanti nelle displasie cervicali.